Treatment of immune neuropathies

Current Opinion in Neurology

Volumn 15, Issue 5, 2002, Pages 623-631

  Van Doorn, Pieter A ^a   Garssen, Marcel P J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic inflammatory demyelinating poly(radiculo)neuropathy; Guillain Barr syndrome; Intravenous immunoglobulin; Methylprednisolone; Miller Fisher syndrome; Multifocal motor neuropathy; Plasma exchange; Steroids

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; IMMUNOGLOBULIN; METHYLPREDNISOLONE; STEROID;

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE NEUROPATHY; MOTOR NEUROPATHY; NEUROPATHY; PLASMAPHERESIS; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; METHYLPREDNISOLONE; NEUROPROTECTIVE AGENTS; PLASMA EXCHANGE; POLYRADICULONEUROPATHY; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PROGNOSIS;

EID: 0036796275     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200210000-00014     Document Type: Review

References (95)

1. Hadden RD, Hughes RA. Treatment of immune-mediated inflammatory neuropathies Curr Opin Neurol 1999; 12:573-579.
2. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fischer syndromes. Lancet 2001; 1:29-37.
3. 1 ganglioside. Ann Neurol 2001; 49:712-720.
4. 1b antibodies in rabbits. Infect Immun 2001; 69:2462-2469.
5. Hartung HP, Kieseier BC, Kiefer R. Progress in Guillain-Barré syndrome. Curr Opin Neurol 2001; 14:597-604.
6. Ho T, Griffin J. Guillain-Barré syndrome. Neurology 1999; 12:389-394.
7. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000; 54:943-949.
8. Merkies IS, Schmitz PI, Van Der Meche FG, et al. Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve 2002; 25:370-377.
9. Merkies ISJ, Schmitz PI, van der Meche FG, et al. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002; 72:596-601.
10. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:195-201.
11. Hahn AF. Guillain-Barré syndrome. Lancet 1998; 352:635-641.
12. Chalela JA. Pearls and pitfalls in the intensive care management of Guillain-Barré syndrome. Semin Neurol 2001; 4:399-405.
13. Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001; 58:893-898.
14. Wilmshurst JM, Thomas NH, Robinson RO, et al. Clinical observations: lower limb and back pain in Guillain-Barré syndrome and associated contrast enhancement in MRI of the cauda equina. Acta Pæediatr 2001; 90:691-703.
15. Ho T, Griffin J. Guillain-Barré syndrome. Curr Opin Neurol 1999; 12:389-394.
16. Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, issue 2. Oxford: Update Software Ltd; 2002. http://www.update-software.com/abstracts/ab001798.htm [accessed 7 July 2002]
17. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35:1096-1104.
18. Anonymous. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1987; 22:753-761.
19. Van der Meché FGA, Schmitz PIM. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992; 326:1123-1129.
20. Anonymous. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997; 349:225-230.
21. Hughes RAC, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, issue 2. Oxford: Update Software Ltd; 2002. http://www.update-software.com/abstracts/ab002063.htm [accessed 7 July 2002]
22. Van Koningsveld R, van Doorn PA, Schmitz PIM, van der Meché FGA. Changes in referral pattern and its effect on outcome in patients with Guillain-Barré syndrome. Neurology 2001; 56:564-566.
23. Latov N, Chaudhry V, Koski CL, et al. Use of intravenous gamma globulins in neuroimmunologic diseases. J Allergy Clin Immunol 2001; 108(suppl):S126-S132.
24. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755.
25. Raphaël JC, Chevret S, Harboun M, et al. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001; 71:235-238.
26. Anonymous. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group. Lancet 1993; 341:586-590.
27. Hughes RAC, van der Meché FGA. Corticosteroids for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, issue 2. Oxford: Update Software Ltd; 2002. http://www.update-software.com/abstracts/ab001446.htm [accessed 7 July 2002]
28. Anonymous. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Guillain-Barré Study Group. Ann Neurol 1994; 35:749-752.
29. Wollinsky KH, Hülser PJ, Brinkmeier H, et al. CFS filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 2002; 57:774-780.
30. Feasby TE, Hartung HP. Drain the roots: a new treatment for Guillain-Barré syndrome? [Editorial]. Neurology 2001; 57:753-754.
31. Brinkmeier H, Aulkemeyer P, Wollinsky KH, Rudel R. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat Med 2000; 7:808-811.
32. Berciano J. CFS filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial [letter to editor]. Neurology 2002; 58:988-989.
33. Kieseier BC, Tani M, Mahad D, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002; 125:823-834.
34. Diener HC, Haupt WF, Kloss TM, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol 2001; 46:107-109.
35. Schaller B, Radziwill AJ, Steck AJ. Successful treatment of Guillain-Barré syndrome with combined administration of Interferon-β-1a and intravenous immunoglobulin. Eur Neurol 2001; 46:167-168.
36. Créange A, Chazaud B, Plonquet A, et al. IFN-β decreases adhesion and transmigration capacities of lymphocytes in Guillain-Barré syndrome. Neurology 2001; 57:1704-1706.
37. Miyamoto K, Oka N, Kawasaki T, et al. New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 2002; 25:280-282.
38. Green DM, Ropper AH. Mild Guillain-Barré syndrome. Arch Neurol 2001; 58:1098-1101.
39. Van Koningsveld R, Schmitz PI, Ang CW, et al. Infections and course of disease in mild forms of Guillain-Barré syndrome. Neurology 2002; 58:610-614.
40. Anonymous. Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1997; 41:298-306.
41. Merkies IS, Schmitz PI, Samijn JP, et al. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999; 53:1648-1654.
42. Van der Meché FGA, van Doorn PA. Guillian-Barré syndrome and chronic inflammatory demeyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995; 37(suppl 1):S14-S31.
43. Mori K, Hattori N, Sugiura M, et al. Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 2002; 58:979-982.
44. Van der Meché FGA, Van Doorn PA, Meulstee J, et al. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 2001; 45:133-139.
45. Yuan CL, Wang YJ, Tsai CP. Miller Fisher syndrome: a hospital-based retrospective study. Eur Neurol 2000; 44:79-85.
46. Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller-Fisher syndrome. Neurology 2001; 56:1104-1106.
47. Buchwald B, Buffer J, Carpo M, et al. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 2001; 56:67-74.
48. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol 2002; 51:673-680.
49. Plomp JJ, Molenaar PC, O'Hanlon GH, et al. Anti-GQ1b antibodies from patients with Miller Fisher syndrome exert α-laterotoxin-like effects on transmitter release at the mouse neuromuscular junction. Ann Neurol 1998; 45:189-199.
50. Jacobs BC, Bullens RW, O'Hanlon GM, et al. Detection and prevalence of α-latrotoxin-like effects of serum from patients with Guillain-Barré syndrome. Muscle Nerve 2002; 25:549-558.
51. 1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve termina. Brain 2001; 124:893-906.
52. Dalakas MC. Blockade of blocking antibodies in Guillain-Barré syndromes: unblocking the mystery of action of intravenous immunoglobulin. Ann Neurol 2002; 51:667-669.
53. 1b IgG antibody. J Neurol 2001; 248:148-150.
54. Sheikh KA, Griffin JW. Variants of the Guillain-Barré syndrome: progress toward fulfilling 'Koch's postulates'. Ann Neurol 2001; 49:694-696.
55. Pollard JD. Chronic inflammatory demyelinating polyradiculoneuropathy. Curr Opin Neurol 2002; 3:279-283.
56. Hughes RAC. Chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:281-282.
57. Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol 2002; 249:245-253.
58. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24:311-324.
59. Franssen H, Vermeulen M, Jennekens FGI. Chronic inflammatory neuropathies. In: Emery AEH, editor. Diagnostic criteria for neuromuscular disorders, 2nd ed. London: Royal Society of Medicine Press; 1997. pp. 53-59.
60. Nicolas G, Maisonobe T, Le Forestier N, et al. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2001; 25:26-30.
61. Nobile-Orazio E, Carpo M. Neuropathy and monoclonal gammopathy. Curr Opin Neurol 2001; 5:615-620.
62. Notermans NC, Franssen H, Eurelings M, et al. Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy. Muscle Nerve 2000; 1:73-79.
63. Eurelings M, Notermans NC, van de Donk NW, Lokhorst HM. Risk factors for hematological malignancy in polyneuropathy. Muscle Nerve 2001; 10:1295-1302.
64. Van den Berg-Vos RM, Van den Berg LH, Franssen H, et al. Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? Neurology 2000; 54:26-32.
65. Dyck PJ, Dyck PJB. Atypical varieties of chronic inflammatory demyelinating neuropathies. Lancet 2000; 355:1293-1294.
66. Sabatelli M, Madia F, Mignogna T, et al. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol 2001; 248:772-777.
67. Ohkoshi N, Harada K, Nagata H, et al. Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy; clinical features and pathological study of the sural nerves. Eur Neurol 2001; 45:241-248.
68. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11:136-141.
69. Mehndiratta MM, Hughes RAC. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). In: The Cochrane Library, issue 2. Oxford: Update Software Ltd; 2002. http://www.update-software.com/abstracts/ab002062.htm [accessed 7 July 2002]
70. Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314:461-465.
71. Hahn AF, Bolton OF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119:1055-1066.
72. Dyck P J, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36:838-845.
73. van Doorn PA, Brand A, Strengers PF, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind placebo-controlled crossover study. Neurology 1990; 40:209-212.
74. Hahn AF, Bolton CF, Zochodne D, Faesby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo controlled, cross-over study. Brain 1996; 119:1067-1077.
75. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56:445-449.
76. Van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). In: The Cochrane Library, issue 2. Oxford: Update Software Ltd; 2002. http://www.update-software.com/abstracts/ab001797.htm [accessed 7 July 2002]
77. Hadden RD, Bensa S, Lunn MP, Hughes RA. Immunoadsorption inferior to plasma exchange in a patient with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2002; 72:644-646.
78. Hahn FH. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 1998; 51(suppl 5):S16-S21.
79. Van den Bergh PYK. Intravenous immunoglobulin (IVIG) in the treatment of chronic demyelinating polyradiculoneuropathy. Acta Neurol Belg 2001; 101:147-151.
80. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001; 185:119-122.
81. Vermeulen M, van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002; 72:127-128.
82. Sghirlanzoni A, Solari A, Ciano C, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol Sci 2000; 21:31-37.
83. Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001; 184:57-63.
84. Andrade R, Gongalez I, Machado A, Garcia A. Can sural nerve biopsy be used to orientate the treatment of chronic inflammatory demyelinating polyneuropathy? Rev Neurol 2001; 33:1005-1009.
85. Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999; 52:498-503.
86. Kuwabara S, Ogawara K, Misawa S, et al. Distribution patterns of demyelinisation correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002; 72:37-42.
87. Van den Berg-Vos RM, Franssen H, Visser J, et al. Disease severity in multifocal motor neuropathy and its association with the response to treatment. J Neurol 2002; 3:330-336.
88. Umapathi T, Hughes RAC, Nobile-Orazio E, Léger JM. Immunosuppressive treatment for multifocal motor neuropathy (Cochrane Review). In: The Cochrane Library, issue 2. Oxford: Update Software Ltd; 2002. http://www.update-software.com/abstracts/ab003217.htm [accessed 7 July 2002]
89. Van den Berg LH, Franssen H, Wokke JHJ. Improvement of multifocal motor neuropathy during long-term weekly treatment with intravenous immunoglobulin. Neurology 1995; 45:987-988.
90. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000; 9:1256-1262.
91. Leger JM, Chassande B, Musset L, etal. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001; 124:145-153.
92. Van Doorn PA, van der Meché FG. IVIg treatment improves multifocal motor neuropathy: easy to start but difficult to stop [Editorial]. Neurology 2000; 55:1246-1247.
93. th ENMC International Workshop: multifocal motor neuropathy. 14-15 April 2000, Hilversum, The Netherlands. Neuromuscul Disord 2001; 11:309-314.
94. Van den Berg-Vos RM, Franssen H, Wokke JH, et al. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 2000; 6:919-926.
95. Nobile-Orazio E, Cappellari A, Meucci N, et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 2002; 6:761-766.